Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Incyte is a provider of genomic information-based tools and services, including database products, bioinformatics software, and microarray-based gene expression services. The company serves pharmaceutical, biotechnology, and agricultural companies to accelerate drug discovery. As of December 31, 1998, the company had 22 multi-year database collaboration agreements.
Key Financial Metrics
| Metric (in thousands) | 1998 | 1997 | 1996 |
|---|---|---|---|
| Revenues | $134,811 | $89,996 | $41,895 |
| Net Income (Loss) | $3,472 | $6,908 | $(7,276) |
| Operating Income (Loss) | $32 | $3,616 | $(9,564) |
| Research & Development Expenses | $97,192 | $72,452 | $41,337 |
| Cash, Cash Equivalents & Securities | $111,233 | $113,095 | $40,238 |
| Working Capital | $81,437 | $90,700 | $21,351 |
| Net Cash Provided by Operating Activities | $36,233 | $17,987 | $18,527 |
| Basic EPS | $0.13 | $0.28 | $(0.32) |
Note: 1998 results include a one-time charge of $10.978 million for the purchase of in-process research and development (Hexagen acquisition) and $1.171 million in acquisition-related charges.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 50% to $134.8 million, driven by an increase in the number of database collaboration agreements (from 18 to 22) and expanded microarray services.
- Profitability Decline: Net income decreased 49.7% to $3.5 million. This decline was primarily due to the $11.0 million charge for in-process R&D related to the Hexagen acquisition and increased R&D spending ($97.2 million vs. $72.5 million in 1997).
- Acquisitions: Completed the acquisition of Hexagen Limited (SNP discovery) in September 1998 and Synteni, Inc. (microarray technology) in January 1998 (accounted for as a pooling of interests).
- Joint Venture Losses: Losses from the diaDexus joint venture increased to $1.5 million in 1998 from $0.3 million in 1997.
Guidance, Outlook, and Risks
- 2000 Outlook: Management expects to report a net loss of approximately $20 million for 1999 due to a planned $45 million investment in genomic sequencing, mapping, and SNP discovery programs. A return to profitability is projected for the second half of 2000.
- Patent Litigation: Incyte is involved in significant patent infringement lawsuits filed by Affymetrix, Inc. in January and September 1998 regarding microarray technology. The company cannot estimate potential losses but expects substantial legal expenses and diversion of management attention.
- Customer Concentration: One customer contributed 12% of total revenues in 1998. No single customer contributed more than 10% in 1997.
- Year 2000 Compliance: The company estimates costs between $1.0 million and $1.5 million to ensure Year 2000 compliance, with no material expenditures incurred to date.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of Hexagen's SNP discovery technology and Synteni's microarray operations.
- Litigation Status: Monitor the outcome of the Affymetrix patent lawsuits, specifically the preliminary injunction hearing scheduled for April 30, 1999.
- Revenue Sustainability: Assess the renewal rates of the 22 database collaboration agreements, as the loss of a single major partner could materially impact results.
- Cash Burn Rate: Confirm that the $111.2 million cash balance is sufficient to fund the projected $45 million R&D investment in 1999 without requiring dilutive equity financing.
- Joint Venture Viability: Review the financial performance of the diaDexus joint venture, which is currently incurring losses.